fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Vericiguat

All products: Limited Use (codes 685)

Verquvo · DIN 02537052 · 5 mg · tablet

Limited Use, Reason for Use code 685 requiredMarketed · checked November 20, 2026
StatusLimited Use, Reason for Use code 685 required
Write on scriptReason for Use code 685 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 685
Reason for Use code 685 For the treatment of symptomatic chronic heart failure (HF) as an adjunct to standard-of-care therapy in adult patients with reduced ejection fraction who are stabilized after a recent HF decompensation event, if all the following conditions are met: (a) Left ventricular ejection fraction (LVEF) less than 45%; (b) New York Heart Association (NYHA) class II to IV symptoms; (c) HF decompensation event requiring hospitalization within the previous 6 months and/or intravenous diuretic treatment for HF (without hospitalization) within the previous 3 months; (d) Vericiquat is used in combination with standard-of-care* HF therapy; and (e) Initiated under the supervision of a prescriber who is experienced in the management of HF. * Standard-of-care HF therapy includes one medication from each of the following categories, unless there is a contraindication or intolerance: (a) angiotensin receptor-neprilysin inhibitor (ARNI) or angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB); (b) beta blocker; (c) mineralocorticoid receptor antagonist (MRA); and (d) sodium-glucose cotransporter-2 (SGLT2) inhibitor Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Verquvo · DIN 02537052 Manufacturer: Bayer Inc., Health Care Division; listing date 2024-09-27 Health Canada: Marketed since 2023-09-19 · brand VERQUVO · ATC C01DX22 VERICIGUAT · form Tablet · route Oral · ingredients VERICIGUAT 5 MG · company Bayer inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Verquvo: Formulary list price $4.83 per unit (the source does not state the unit; exact figure $4.8300). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02537052)

Source record
DIN 02537052: Verquvo Raw flags: sec12=Y, sec3=Y Item: 241200114; group id 373; item number 0889; lccId 00400; manufacturer id BAH Source form: Tab; strength: 5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $4.8300; ministry $4.8300 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02537052 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102576
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (C01D): coverage varies; not interchangeable

  • Isosorbide dinitrate (Isdn): general benefit, not a benefit
  • Nitroglycerin (Transderm-Nitro): general benefit, not a benefit, listing status unconfirmed
  • Isosorbide + mononitrate (Imdur): not a benefit
Other drugs in the same formulary class (24:12 Vasodilating Drugs) and how they are covered

Matched class: 24:12 Vasodilating Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Some products covered without a code (check the product listing): ISOSORBIDE DINITRATE, NITROGLYCERIN 24:12 Vasodilating Drugs

ISOSORBIDE DINITRATE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 5mg, 10mg, 30mg · SL Tab, Tab

NITROGLYCERIN

· 20 products · General benefit (13), Temporary benefit (2), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 0.4mg/Hr/20 Sq Cm, 0.6mg/Hr/30 Sq Cm, 0.4mg/Hr/14 Sq Cm, 0.6mg/Hr/21 Sq Cm, 0.3mg, 0.6mg, 0.4mg/Metered Dose, 0.2mg/Hr, 0.4mg/Hr, 0.6mg/Hr, 0.8mg/Hr · Patch, SL Tab, Sp-180 Dose Pk, Sp-75 Dose Pk, Spray-200 Dose Pk, Transdermal Patch

ISOSORBIDE-5-MONONITRATE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 60mg · ER Tab

DIPYRIDAMOLE & ACETYLSALICYLIC ACID

· 2 products · Listed, not a benefit (1), Limited Use, codes 349 (1) · strengths: 200mg/25mg · Cap

NIMODIPINE

· 1 products · Limited Use, codes 42, 43 · strengths: 30mg · Tab

AMBRISENTAN

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · Tab

BETAHISTINE DIHYDROCHLORIDE

· 24 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 8mg, 16mg, 24mg · Tab

BOSENTAN MONOHYDRATE

· 14 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 62.5mg, 125mg · Tab

DIPYRIDAMOLE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 25mg, 50mg, 75mg · Tab

RIOCIGUAT

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.5mg, 1.5mg, 1mg, 2.5mg, 2mg · Tab

TADALAFIL

· 73 products · Off-Formulary Interchangeable, not an ODB benefit (72), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

VARDENAFIL HCL

· 16 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg, 5mg, 20mg · Orally Disintergrating Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:12
Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS VERQUVO (vericiguat) is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent heart failure decompensation event requiring hospitalization and/or intravenous diuretic therapy. VERQUVO should be used in combination with standard of care therapy for heart failure. VERQUVO should be initiated under the supervision of a healthcare professional who is experienced in the management of heart failure (see 4.1 Dosing Considerations). 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (≥ 65 years of age): In VICTORIA, a total of 1,596 (63%) patients treated with VERQUVO were 65 years and older and 783 (31%) patients treated with VERQUVO were 75 years and older. No overall differences in safety or efficacy of VERQUVO were observed between patients aged 65 years and older compared to younger patients, but greater sensitivity of some older individuals cannot be ruled out. https://pdf.hres.ca/dpd_pm/00070443.PDF PM date: not printed or not captured Source product: VERQUVO; DIN 02537044; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18